1. Home
  2. BFRI vs INTS Comparison

BFRI vs INTS Comparison

Compare BFRI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$1.11

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFRI
INTS
Founded
1997
2012
Country
United States
United States
Employees
94
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
12.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BFRI
INTS
Price
$1.11
$4.72
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$2.75
$38.00
AVG Volume (30 Days)
374.9K
64.3K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.36
N/A
Revenue Next Year
$16.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.19
52 Week High
$1.21
$8.06

Technical Indicators

Market Signals
Indicator
BFRI
INTS
Relative Strength Index (RSI) 59.88 66.87
Support Level $0.77 $4.50
Resistance Level $1.13 $8.06
Average True Range (ATR) 0.10 0.23
MACD 0.02 0.13
Stochastic Oscillator 69.94 83.34

Price Performance

Historical Comparison
BFRI
INTS

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: